This inventor holds 55 USPTO granted patents and 32 published patent applications, plus 15 CIPO patents and 28 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Gilead Sciences, Inc., Gilead Pharmasset LLC, Pfizer Corporation. Active years: 2011-2025.
Location History:
- Foster City, CA (US) (2012)
- San Francisco, CA (US) (2011 - 2024)
- Burlingame, CA (US) (2017 - 2024)
Company Filing History:
50 out of 946 
4 out of 81 
1 out of 4,486 
Years Active: 2011-2025
Areas of Expertise:
Title: The Innovative Contributions of Scott E. Lazerwith
Introduction
Scott E. Lazerwith, based in Burlingame, California, is a prominent inventor recognized for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 49 patents, Lazerwith has made substantial strides in the development of therapeutic compounds aimed at combating various viral infections.
Latest Patents
Among his latest innovations, Lazerwith has developed phospholipid compounds, which encompass pharmaceutical compositions with potential applications in treating viral infections. This patent outlines the methodologies for synthesizing and utilizing these compounds to address infections caused by numerous viral families, including paramyxoviridae, pneumoviridae, picornaviridae, flaviviridae, filoviridae, arenaviridae, orthomyxovirus, and coronaviridae.
Another recent patent focuses on substituted pyrrolizine compounds, which are designed to inhibit hepatitis B virus (HBV) replication. The application details both the pharmaceutical compositions and the production methods for these compounds, highlighting their importance in antiviral research and therapy.
Career Highlights
Scott E. Lazerwith has held positions at several noteworthy companies, including Gilead Sciences, Inc. and Gilead Pharmasset LLC. His experience in these leading pharmaceutical firms has equipped him with the expertise to innovate and drive research forward in the quest for effective antiviral treatments.
Collaborations
During his career, Lazerwith has had the opportunity to collaborate with other accomplished professionals in the field, including Hyung-Jung Pyun and William John Watkins. These partnerships reflect a shared commitment to advancing research in pharmaceuticals and enhancing therapeutic applications for global health initiatives.
Conclusion
Scott E. Lazerwith continues to be a vital contributor to the realm of pharmaceutical inventions, with a strong emphasis on innovation in antiviral therapies. His extensive patent portfolio not only signifies his dedication to scientific advancement but also underscores the potential impact of his work in improving public health outcomes.